Mulangu S, Dodd LE, Davey, Jr RT, et al. - In this randomized, controlled trial involving individuals of any age who had a positive outcome for Ebola virus RNA on reverse-transcriptase–polymerase-chain-reaction assay, experts evaluated the safety and efficiency of the most promising therapies for Ebola virus disease (EVD): MAb114 (a single human monoclonal antibody derived from an Ebola survivor), REGN-EB3 (a co-formulated mixture of three human IgG1 monoclonal antibodies), and ZMapp (a triple monoclonal antibody agent). A total of 681 people were recruited from November 20, 2018, to August 9, 2019. A shorter duration of symptoms prior to the admission and lower baseline values for viral load and for serum creatinine and aminotransferase levels each correlated to enhanced survival. Moreover, in decreasing mortality from EVD, both MAb114 and REGN-EB3 were superior to ZMapp.